NCT03041688 2026-04-13
Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
114 trialsNCT05453903 2026-04-13
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06514261 2026-04-13
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06651229 2026-04-13
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06802523 2026-04-13
Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Suspended
NCT07513129 2026-04-13
A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And Lymphomas
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07177079 2026-04-09
High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)
University of Iowa
Phase 1 Recruiting
NCT06419634 2026-04-08
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Bristol-Myers Squibb
Phase 1 Recruiting
NCT06763341 2026-04-08
A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1 Suspended
NCT04227847 2026-04-07
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
Seagen Inc.
Phase 1 Recruiting
NCT07511062 2026-04-06
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
Northside Hospital, Inc.
Phase 1 Not yet recruiting
NCT07374029 2026-04-03
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
Beth Israel Deaconess Medical Center
Phase 1 Not yet recruiting
NCT05091424 2026-04-02
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 1 Recruiting
NCT03874052 2026-03-24
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
OHSU Knight Cancer Institute
Phase 1 Recruiting
NCT05275439 2026-03-18
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Shattuck Labs, Inc.
Phase 1 Terminated
NCT06152809 2026-03-18
CIML NK Cells With Venetoclax for AML
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT03547115 2026-03-17
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
MEI Pharma, Inc.
Phase 1 Terminated
NCT04926285 2026-03-16
VEN-OM
University of Illinois at Chicago
Phase 1 Completed
NCT05735184 2026-03-13
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc.
Phase 1 Recruiting
NCT05292664 2026-03-12
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT05834244 2026-03-11
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03969446 2026-03-05
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
City of Hope Medical Center
Phase 1 Recruiting
NCT03844815 2026-03-04
Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia
University of Chicago
Phase 1 Active not recruiting
NCT06177067 2026-03-04
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT07044544 2026-03-04
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
University of Alabama at Birmingham
Phase 1 Recruiting
NCT07283094 2026-03-03
FHD-286
Montefiore Medical Center
Phase 1 Recruiting
NCT07439211 2026-03-03
GAVEL
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT06445907 2026-02-24
Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04964505 2026-02-23
Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia
University of California, Davis
Phase 1 Terminated
NCT03826992 2026-02-18
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
Children's Hospital Medical Center, Cincinnati
Phase 1 Recruiting
NCT06191978 2026-02-18
A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04872790 2026-02-10
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
OHSU Knight Cancer Institute
Phase 1 Recruiting
NCT06372717 2026-02-04
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
Apollo Therapeutics Ltd
Phase 1 Recruiting
NCT05455294 2026-01-28
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT04898894 2026-01-26
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Phase 1 Active not recruiting
NCT05665530 2026-01-26
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Prelude Therapeutics
Phase 1 Completed
NCT05001828 2026-01-21
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia
Polaris Group
Phase 1 Active not recruiting
NCT03709758 2026-01-16
Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT06429449 2026-01-15
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
University of Colorado, Denver
Phase 1 Recruiting
NCT05010772 2026-01-14
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05317403 2026-01-12
Venetoclax to Augment Epigenetic Modification and Chemotherapy
Medical College of Wisconsin
Phase 1 Recruiting
NCT05263284 2026-01-08
8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1 Recruiting
NCT05342584 2026-01-08
Venetoclax AML
Montefiore Medical Center
Phase 1 Recruiting
NCT05597306 2026-01-08
VenBom
University of Miami
Phase 1 Recruiting
NCT04843904 2026-01-07
SAVE
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT07320235 2026-01-06
IMAGINE
Icahn School of Medicine at Mount Sinai
Phase 1 Recruiting
NCT03613532 2025-12-24
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT02296918 2025-12-19
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
Acerta Pharma BV
Phase 1 Completed
NCT06448013 2025-12-15
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05564650 2025-12-08
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Thomas Jefferson University
Phase 1 Active not recruiting